The Pro Medicus Ltd (ASX: PME) share price is in focus after the company announced a new 5-year, A$10 million enterprise contract, expanding its European presence.
What did Pro Medicus report?
- Signed a 5-year, A$10 million Enterprise PACS contract with University Hospital Heidelberg (UKHD) and German Cancer Research Institute (DKFZ)
- The deal includes associated hospitals Thoraxklinik Heidelberg and KKH Bergstrasse
- Pro Medicus will replace and consolidate three legacy PACS systems
- This expands the Visage Imaging platform's footprint in the German and European hospital markets
What else do investors need to know?
University Hospital Heidelberg is one of Germany's largest academic medical centres, offering significant exposure for Pro Medicus in Europe. The new contract includes not only the main hospital but partner research institutions and associated clinics, broadening the company's reach.
Pro Medicus' Visage 7 platform will enable UKHD and DKFZ to streamline clinical workflows, allowing clinicians and researchers fast, unified access to large volumes of imaging data. This move aims to help translate medical discoveries into direct improvements in patient care more rapidly.
What did Pro Medicus management say?
Dr Sam Hupert, CEO of Pro Medicus Limited, said
We are honoured to partner with UKHD and DKFZ, one of Europe's most important medical and cancer research centers. Visage 7 is uniquely positioned to deliver both the diagnostic performance and the research capabilities required by leading academic medical centers. Together, we are shaping the future of enterprise imaging and help empowering clinicians and researchers to deliver better care.
What's next for Pro Medicus?
Pro Medicus aims to leverage this partnership as a springboard for further growth in Europe's healthcare imaging market. Management is focused on delivering scalable, efficient solutions for large research-based hospitals, supporting both clinical care and scientific innovation.
With this latest deal, Pro Medicus continues to strengthen its presence worldwide, capitalising on its innovative Visage platform and longstanding health technology expertise.
Pro Medicus share price snapshot
Pro Medicus shares have soared 66% over the past year, far outpacing the S&P/ASX 200 Index (ASX: XJO) which has risen around 10% over the same period.
